

**SOLVING OF CERTAIN ANALYTICAL
DIFFICULTIES IN PHARMACEUTICAL QUALITY
CONTROL LABORATORIES**
Thesis

Presented for the Partial Fulfillment of Master Degree
In
Pharmaceutical Sciences
(Analytical Chemistry)

By

Eman Galal Noman

B. Pharm. Sci., (2003)
Faculty of Pharmacy, Cairo University

Under Supervision of

Prof. Dr. Ezzat Abd El-Moety

Professor of Analytical Chemistry
Faculty of Pharmacy
Cairo University

Ass.Prof. Dr. Hayam Mahmoud Lotfy

Assistant Professor of Analytical Chemistry
Faculty of Pharmacy
Cairo University

Department of Analytical Chemistry

**Faculty of Pharmacy
Cairo University
2010**

ACKNOWLEDGEMENT

I deeply feel indebted to Allah, the most merciful and the most generous. I praise him for his favors and ask him to increase his grace and generosity.

I would like to express my deepest and sincere gratitude to **Prof. Dr. Ezzat Abd El-Moety**, Professor of Analytical Chemistry, Faculty of Pharmacy-Cairo University, for his great supervision, continuous encouragement and valuable comments. It is a great honor to work under his supervision and guidance.

I want also to express my deepest appreciation and my thanks to **Dr. Hayam Mohamad Lotfy** Assistant Professor of Analytical Chemistry, Faculty of Pharmacy- Cairo University, for her kind guidance and encouragement and for her valuable advices and supervision.

I am very grateful to my mother, father, husband, all my family specially my lovely small daughter **Jana** for their love, continuous help, patience, and kind support.

I like to thank my colleagues in The Arab Drug Company for their encouragement and support.

Eman Galal Noman

2010

List of Abbreviations

ANA	: Analgin
BETA	: Betamethasone valerate
BHA	: Butylated hydroxyl aniline
BHT	: Butylated hydroxyl toluene
BIPER	: Biperiden hydrochloride
BP	: British pharmacopeia
CAF	: Caffeine
CE	: Capillary electrophoresis
CLIO	: Clioquinol
Deg.	: Degradation product
DOM	: Domperidone
EDTA	: Ethylenediamine tetra acetic acid
ERG.TAR	: Ergotamine tartarate
F	: Variance ratio
FDA	: Food and drug administration
FID	: Flame ionization detector
US	: United states
GC	: Gas chromatography
GMP	: Good manufacturing process
GQM	: Good quality management
HPLC	: High performance liquid chromatography

HPTLC	: High performance thin layer chromatography
IR	: Infra red
K	: Capacity factor
LC	: Liquid chromatography
LOD	: Limit of detection
LOQ	: Limit of quantification
MPB	: Methyl paraben
MTG	: Monothioglycerol
ODS	: Octadecyl silane
PAR	: Paracetamol
PDCA	: Plan-Do-Check-Act
PPB	: Propyl paraben
PRED	: Prednisolone
PROM	: Promethazine hydrochloride
QA	: Quality assurance
QC	: Quality control
R&D	: Research and development
R_s	: Resolution factor.
RSD	: Relative standard deviation.
SAL	: Salicylic acid
TFA	: Tetraflouroacetic acid
THF	: Tetrahydrofuran.
t	: Student's t-test.

TLC	: Thin layer chromatography
USP	: United states pharmacopeia
UV	: Ultraviolet
VIT.E	: Vitamin E acetate

Contents

Page

PART I

GENERAL INTRODUCTION

I.1.	The pharmaceutical industry	1
I.2.	Quality	1
I.3.	Relationship between good quality management, quality assurance, good manufacturing practice and quality control.....	2
I.3.1.	Quality Assurance	3
I.3.2.	Quality Control	3
I.3.3.	Research and Development Section (R&D).....	5
I.4	Good Quality Management Cycle.....	7
I.5	Drug Stability and Stability Indication.....	8
I.5.1.	Purposes of stability testing.....	8
I.5.2.	Stability Studies.....	9
I.5.3.	Accelerated Stability Studies.....	9
I.6.	Routs of Drug Instability in Dosage Forms.....	10
I.7.	Analysis of Multicomponent Mixtures.....	10

PART II

AIM OF WORK

PART III

SOLVED ANALYTICAL DIFFICULTIES

SECTION III-1

STABILITY STUDIES ON PROMETHAZINE HYDROCHLORIDE IN SYRUP DOSAGE FORM

II-1.1.	Literature review of drugs under investigation.....	13
III-1.1.1	Promethazine Hydrochloride (PROM).....	13
III-1.1.2	Sodium Benzoate (S.BENZ).....	16
III-1.2.	Selective HPLC-Quantification of Promethazine Hydrochloride and Sodium Benzoate in Presence of Promethazine Hydrochloride Oxidative Degradation Products.....	21
III-1.2.1	Introduction	21
III-1.2.2	Experimental.....	22
III-1.2.2.1.	Instruments.....	22
III-1.2.2.2.	Chromatographic Conditions	22
III-1.2.2.3.	Chemicals and Reagents.....	22
III-1.2.2.4.	Samples.....	23
III-1.2.2.5	Preparation of the oxidative degradation products of promethazine hydrochloride.....	23
III-1.2.2.6	Standard Stock Solutions.....	24
III-1.2.2.7	Preparation of laboratory prepared mixtures of promethazine hydrochloride and sodium benzoate.....	24

III-1.2.2.8	Preparation of laboratory prepared mixtures of promethazine hydrochloride and its oxidative degradation products in presence of sodium benzoate.....	25
III-1.2.3.	Procedures	25
III-1.2.3.1	Construction of calibration graphs	25
III-1.2.3.2	Analysis of laboratory prepared mixtures of promethazine hydrochloride and sodium benzoate	25
III-1.2.3.3	Analysis of laboratory prepared mixtures of promethazine hydrochloride and its oxidative degradation products in presence of sodium benzoate.....	26
III-1.2.3.4	Determination of promethazine hydrochloride and sodium benzoate in their pharmaceutical preparation (Expectyl [®] syrup).....	26
III-1.2.4.	Results and Discussion.....	27
III-1.2.4.1.	Method Optimization.....	27
III-1.2.4.2.	System Suitability and Final Assay Conditions.....	28
III-1.2.4.3.	Validation Parameters.....	28
III-1.2.5.	Conclusion.....	30
III-1.3.	Enhancement of Promethazine Hydrochloride Stability in Syrup Dosage Form.....	43
III-1.3.1	Introduction.....	43
III-1.3.2.	Experimental.....	45
III-1.3.2.1.	Instruments.....	45
III-1.3.2.2.	Chemicals and Materials.....	45
III-1.3.2.3.	Experimental Conditions.....	46
III-1.3.2.4.	Optimization of The Formula.....	46
III-1.3.3.	Results and Discussion.....	48
III-1.3.3.2.	Effect of caramel color.....	48
III-1.3.3.3.	Effect of senega extract and tincture squill.....	49
III-1.3.3.4.	Effect of addition of different antioxidants to the formula.....	49

III-1.3.4	Conclusion.....	50
-----------	-----------------	----

SECTION III-2

SIMULTANEOUS STABILITY-INDICATING DETERMINATION OF BETAMETHASONE-17 VALERATE, CLIOQUINOL, METHYL AND PROPYL PARABENS BY LIQUID CHROMATOGRAPHY

III-2.1.	Literature review of drugs under investigation.....	59
III-2.1.1.	Betamethasone valerate (BETA)	59
III-2.1.2.	Clioquinol (CLIO).....	62
III-2.1.3.	Methyl paraben (MPB).....	66
III-2.1.4.	Propyl paraben (PPB).....	66
III.2.2.	Simultaneous Stability Indicating Determination of Betamethasone-17 Valerate, Clioquinol, Methyl and Propyl Parabens by Liquid Chromatography.....	69
III.2.2.1.	Introduction.....	69
III-2.2.2.	Experimental.....	70
III-2.2.2.1.	Instruments	70
III-2.2.2.2.	Chromatographic Conditions	70
III-2.2.2.3.	Chemicals and Reagents	71
III-2.2.2.4.	Samples	71
III-2.2.2.5.	Preparation of degradation products of betamethasone-17 valerate and clioquinol.....	72
III-2.2.2.6.	Standard Stock Solutions	73
III-2.2.2.7.	Working standard solutions.....	74
III-2.2.2.7.	Preparation of laboratory prepared mixtures of betamethasone-17 valerate, clioquinol, MPB and PPB.....	75

III-2.2.2.8.	Preparation of laboratory prepared mixtures of betamethasone-17 valerate, its thermal degradation products, clioquinol, its photo-degradation products, MPB and PPB	75
III-2.2.3.	Procedures	75
III-2.2.3.1.	Construction of calibration graphs.....	75
III-2.2.3.2.	Analysis of laboratory prepared mixtures of betamethasone-17 valerate, clioquinol, MPB and PPB.....	76
III-2.2.3.3.	Analysis of laboratory prepared mixtures of betamethasone-17 valerate, its thermal degradation products, clioquinol, its photo-degradation products, MPB and PPB.....	76
III-2.2.3.4.	Determination of betamethasone-17 valerate, clioquinol, MPB and PPB in their pharmaceutical preparation (Betaval -C [®] cream).....	77
III-2.2.3.5.	Determination of betamethasone-17 valerate and clioquinol in their pharmaceutical preparation (Betaval -C [®] ointment).	77
III-2.2.3.6.	Determination of betamethasone-17 valerate and clioquinol in their pharmaceutical preparation (Quadriderm [®] cream)...	77
III-2.2.3.7.	Determination of betamethasone-17 valerate and clioquinol in their pharmaceutical preparation (Betnovate -C [®] cream).	78
III-2.2.3.	Results And Discussion.....	78
III-2.2.4.1.	Method Optimization.....	79
III-2.2.4.2.	System Suitability and Final Assay Conditions.....	81
III-2.2.4.3.	Validation Parameters.....	81
III-2.2.5.	Conclusion.....	83

SECTION III-3

SIMULTANEOUS STABILITY-INDICATING DETERMINATION OF CLIOQUINOL, PREDNISOLONE, AND VITAMIN E ACETATE BY LIQUID CHROMATOGRAPHY

III-3.1.	Literature review of drugs under investigation	110
III-3.1.1.	Clioquinol (CLIO).....	110
III-3.1.2.	Prednisolone (PRED).....	110
III-3.1.3.	Vitamin E acetate [alpha Tocopherol Acetate] (VIT.E).....	116
III-3.2.	Simultaneous stability-indicating determination of clioquinol, prednisolone and vitamin E acetate by liquid chromatography.....	120
III-3.2.1.	Introduction.....	120
III-3.2.2.	Experimental	121
III-3.2.2.1.	Instruments	121
III-3.2.2.2.	Chromatographic Conditions	121
III-3.2.2.3.	Chemicals and Reagents.....	122
III-3.2.2.4.	Samples.....	122
III-3.2.2.5.	Preparation of degradation products of clioquinol and prednisolone.....	123
III-3.2.2.6.	Standard Stock Solutions.....	124
III-3.2.2.7.	Preparation of laboratory prepared mixtures of clioquinol, prednisolone and vitamin E acetate.....	125
III-3.2.2.8.	Preparation of laboratory prepared mixtures of clioquinol, its photo-degradation products, prednisolone, its thermal degradation product and vitamin E acetate.....	125
III-3.2.3.	Procedures.....	125
III-3.2.3.1.	Construction of calibration graphs.....	125
III-3.2.3.2.	Analysis of laboratory prepared mixtures of clioquinol, prednisolone and vitamin E acetate.....	126
III-3.2.3.3.	Analysis of laboratory prepared mixtures of clioquinol, its photodegradation products, prednisolone, its thermal degradation products and vitamin E acetate.....	126
III-3.2.3.4.	Determination of clioquinol, prednisolone and vitamin E	

	acetate in their pharmaceutical preparation (Adcoform [®] ointment).....	127
III-3.2.4.	Results and Discussion.....	127
III-3.2.4.1.	Method optimization.....	128
III-3.2.4.2.	System Suitability and Final Assay Conditions.....	129
III-3.2.4.3.	Validation Parameters.....	130
III-3.2.5.	Conclusion.....	132

SECTION III-4

STABILITY STUDIES ON BIPERIDEN HYDROCHLORIDE

III-4.1.	Literature review of drugs under investigation	150
III-4.1.1.	Biperiden hydrochloride (BIPER)	150
III-4.2.	Stability-Indicating HPLC Determination of Biperiden Hydrochloride in Presence of its Oxidative And Acid Degradation Products.....	152
III-4.2.1.	Introduction	152
III-4.2.2.	Experimental	152
III-4.2.2.1.	Instruments	152
III-4.2.2.2.	Chromatographic conditions	153
III-4.2.2.3.	Chemicals And Reagents	153
III-4.2.2.4.	Samples	153
III-4.2.2.5.	Preparation of the degradation products of biperiden hydrochloride	154
III-4.2.2.6.	Standard Stock Solutions	155

III-4.2.2.7.	Preparation of laboratory prepared mixtures of biperiden hydrochloride and its oxidative and acid degradation products.....	155
III-4.2.3.	Procedures	156
III-4.2.3.1.	Construction of calibration graph	156
III-4.2.3.2.	Analysis of laboratory prepared mixtures of biperide hydrochloride and its oxidative and acid degradatio products.....	156
III-4.2.3.3.	Determination of biperiden hydrochloride in its pharmaceutical preparation (Akinitone [®] tablets).....	156
III-5.B.3.4.	Determination of biperiden hydrochloride in its pharmaceutical preparation (Achtinone [®] tablets).....	157
III-4.2.4.	Results and Discussion	157
III-4.2.3.1.	Method Optimization	158
III-4.2.4.2.	System Suitability And Final Assay Condition.....	159
III-4.2.4.3.	Validation Parameters.....	160
III-4.2.5.	Conclusion.....	161
III-4.3.	Kinetic Study of Oxidative and Acid Degradation of Biperiden Hydrochloride.....	182
III-4.3.1.	Introduction.....	182
III-4.3.2.	Experimental.....	182
III-4.3.2.1.	Samples.....	182
III-4.3.2.2.	Instruments and chromatographic conditions.....	182
III-4.3.2.3.	Chemicals and reagents.....	182
III-4.3.3.	Procedures.....	182
III-4.3.4.	Results and Discussion.....	183
III-4.3.4.1.	Determination of rate and kinetic order of oxidative degradation reaction.....	183
III-4.3.4.2.	Determination of rate and kinetic order of acid degradation reaction.....	184

SECTION III-5

SIMULTANEOUS HPLC-DETERMINATION OF ANALGIN, CAFFEINE, DOMPERIDONE, ERGOTAMINE TARTRATE AND PARACETAMOL IN TWO MULTI-COMPONENT MIXTURES

III-5.1.	Literature review of drugs under investigation	188
III-5.1.1.	Analgin [Dipyrone] (ANA).....	188
III-5.1.2.	Caffeine (CAF) and paracetamol (PAR).....	192
III-5.1.3.	Domperidone (DOM).....	199
III-5.1.4.	Ergotamine tartrate (ERG.TAR).....	204
III-5.2.	Simultaneous HPLC-Determination of Analgin, Caffeine, Domperidone, Ergotamine Tartrate and Paracetamol in Two Multi-Component Combinations.....	207
III-5.2.1.	Introduction	207
III-5.2.2.	Experimental	207
III-5.2.2.1.	Instruments	207
III-5.2.2.2.	Chromatographic Conditions	208
III-5.2.2.3	Reagents and solvents	208
III-5.2.2.4.	Samples.....	208
III-5.2.2.5	Standard Stock Solutions.....	209
III-5.2.2.6.	Preparation of laboratory prepared mixtures of analgin, caffeine, domperidone, ergotamine tartrate and paracetamol.	210
III-5.2.3.	Procedures	210
III-5.2.3.1.	Construction of calibration graphs.....	210
III-5.2.3.2.	Analysis of laboratory prepared mixtures of analgin, caffeine, domperidone, ergotamine tartrate and paracetamol.....	211
III-5.2.3.3.	Determination of analgin, caffeine and ergotamine tartrate in their pharmaceutical preparation (Amigraine® tablets).....	211
III-5.2.3.4.	Determination of caffeine, ergotamine tartrate, domperidone and paracetamol in their pharmaceutical	212